Table 1.
Sensitive analyses according to the presence or absence of PHAII Phenotype in the retrospective cohort.
| No PHAII-like phenotype* N=127 | PHAII-like phenotype* N=45 | ||
|---|---|---|---|
| Univariate analyses | p value | ||
| General characteristics | |||
| Age, years | 58 [43-68] | 56 [49-68] | 0.88 |
| Gender M/F, N (%) | 85/42 (66.9/33.1) | 37/8 (82.2/17.7) | 0.05 |
| BMI, kg/m² | 23.7 [21.0-27.8] | 23.7 [21.2-28.5] | 0.83 |
| First transplantation, N (%) |
109 (85.8) | 36 (80.0) | 0.36 |
| Living donors, N (%) | 28 (22) | 8 (17.8) | 0.55 |
| Delayed Graft function, N (%) |
20 (16.1) | 4 (9.5) | 0.29 |
| Expanded criteria donors, N (%) |
61 (50.8) | 21 (50.0) | 0.93 |
| Cardiovascular disease, N (%) |
27 (21.3) | 15 (33.3) | 0.11 |
| Hypertension before transplantation, N (%) |
93 (73.2) | 28 (62.2) | 0.16 |
| Diabetes (including NODAT), N (%) |
40 (31.5) | 11 (24.4) | 0.37 |
| Graft rejection, N (%) | 5 (3.9) | 3 (6.7) | 0.43 |
| eGFR, ml/min per 1.73m2 |
45 [30-55] | 42 [33-53] | 0.67 |
| Presence of proteinuria, N (%) |
44 (34.6) | 12 (26.7) | 0.33 |
| Treatment | |||
| Mycophenolic acid, N (%) |
117 (92.1) | 39 (86.7) | 0.37 |
| Corticosteroids, N (%) | 94 (74.0) | 31 (68.9) | 0.51 |
| TMP-SMX, N (%) | 106 (83.5) | 35 (77.8) | 0.39 |
| PPI use, N (%) | 73 (57.5) | 21 (46.7) | 0.21 |
| Nephropathy, N (%) | |||
| Glomerular | 35 (27.6) | 12 (26.7) | 0.81 |
| Tubulo-interstitial | 17 (13.4) | 6 (13.3) | |
| Vascular | 11 (8.7) | 6 (13.3) | |
| Diabetes | 12 (9.4) | 6 (13.3) | |
| Polycystic kidney disease |
26 (20.5) | 6 (13.3) | |
| Others (including unknown) |
26 (20.5) | 9 (20.0) | |
| Blood pressure | |||
| Hypertension, N (%) | 100 (78.7) | 45 (100) | 0.0008 |
| SBP, mmHg | 133 [126-144] | 142 [130-152] | 0.005 |
| DBP, mmHg | 78 [70-81] | 80 [70-88] | 0.04 |
| Antihypertensive therapies | |||
| Number of antihypertensive agents |
1 [0–2] | 2 [1–2] | 0.04 |
| Calcium channel blocker, N (%) |
50 (39.4) | 24 (53.3) | 0.1 |
| Beta-blocker, N (%) | 50 (39.4) | 27 (60.0) | 0.02 |
| ACE inhibitors or ARB, N (%) |
39 (30.7) | 22 (48.9) | 0.03 |
| Diuretic except thiazides, N (%) |
31 (24.4) | 5 (11.1) | 0.01 |
| Thiazide, N (%) | 7 (5.5) | 5 (11.1) | 0.3 |
| Others, N (%) | 11 (8.7) | 7 (15.6) | 0.26 |
| Acid-base | |||
| Acidosis, N (%) | 82 (64.6) | 45 (100) | <0.0001 |
| Blood [HCO3-], mM | 22 [20-24] | 19 [18-21] | <0.0001 |
| Blood [HCO3-] < 22 mmol/L, N (%) |
51 (40.2) | 37 (82.2) | <0.0001 |
| Alkaline supplementation, N (%) |
61 (48.0) | 32 (71.1) | 0.008 |
| Potassium | |||
| Hyperkalemia, N (%) | 21 (16.5) | 45 (100) | <0.0001 |
| [K+], mM | 4.2 [4-4.44] | 4.8 [4.6-5] | <0.0001 |
| [K+] >4.5 mmol/L, N (%) |
20 (15.7) | 45 (100) | <0.0001 |
| Potassium chelating agent, N (%) |
2 (1.6) | 6 (13.3) | 0.04 |
| Multivariate analysis | Odds ratio [95% CI] | p value | |
| Beta-blocker | 2.1 [1–4.5] | 0.04 | |
| ACE inhibitors or ARB | 2.6 [1.3–5.4] | 0.009 | |
| Diuretic except thiazides |
0.2 [0.1–0.7] | 0.01 | |
Quantitative data are presented as median [IQR]. Qualitative data were expressed as frequency (N) and percentages (%). All quantitative variables were tested using the Mann-Whitney test. For qualitative variables, the Chi-square test was used, except for the following variables, for which Fisher’s exact test was used: Mycophenolic acid, Graft rejection before inclusion, Others antihypertensive therapy, potassium chelating agent use, thiazide use. TMP-SMX, trimethoprim/sulfamethoxazole; PPI, proton pump inhibitor; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate.